Acharya Prashant speaking to a group of students
Mental Wellness

Acharya Prashant Engages with IIT Students on Mental Health and Spiritual Well-being

Acharya Prashant, founder of PrashantAdvait Foundation and former civil service officer, interacted with IIT students on mental health. More than 1000 people from across the country participated in the session. He said that there is a deep connection between the mind and spirituality. The mind can be controlled through spirituality, which strengthens inner peace and […]

Psychiatrist presenting at a medical conference
Mental Wellness

Gedeon Richter: Cariprazine Proves Effective in Treating Dual Diagnosis

New analyses of cariprazine studies were presented by Gedeon Richter Plc. at 32e Annual Congress of the European Psychiatric Association held April 6-9 in Budapest, Hungary. According to scientific posters of the event, cariprazine could be an appropriate treatment not only for early or late schizophrenia, but also for the difficult-to-treat dual diagnosis that combines schizophrenia and […]

Researchers in a laboratory analyzing data on a computer screen
Mental Wellness

A New Generation of Antidepressant Drug Precision Treatment Based on Revolutionary AI Technology is Born

The9 Limited (Nasdaq: NCTY) (“The9”), an established Internet company, today announced that its investee WM Therapeutics Co., Ltd. (未名脑脑) (“WM Therapeutics”) has achieved revolutionary breakthroughs in the proprietarily developed research and development of antidepressant drug precision treatment. WM Therapeutics’ GenAI multi-dimensional omics drug clinical research technology has made significant progress in new clinical trial, bringing new hope […]

NBI-1070770 Phase 2 Study Illustration
Mental Wellness

Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the first patient has been randomized for its Phase 2 clinical study to evaluate the efficacy, safety, and tolerability of investigational compound NBI-1070770 in adults with major depressive disorder. NBI-1070770 is a novel, selective, and orally active, negative allosteric modulator (NAM) of the NR2B subunit-containing N-methyl-D-aspartate (NMDA NR2B) […]

Els for Autism World Autism Month
Mental Wellness

Join Els for Autism® in Celebrating World Autism Month: Creating Opportunities for Inclusion and Acceptance of Individuals with Autism Spectrum Disorder

As we prepare to celebrate World Autism Month this April, Els for Autism invites individuals and families to join us in our mission of creating a world of limitless possibilities for individuals with autism spectrum disorder (ASD) and their families. Through our comprehensive programs and services spanning a lifetime, the Els for Autism team empowers individuals with […]

A researcher in a lab examining EEG/fMRI results on a computer screen, symbolizing Gabather AB's innovative research in psychiatric disorders treatment.
Mental Wellness

Gabather files two new patent applications to secure novel findings on the effects of GT-002 for the treatment of psychiatric disorders

Gabather AB (Nasdaq First North Growth Market: GABA) today reports that two new US provisional patent applications based on novel findings from the EEG/fMRI target engagement study with GT-002, a selective positive allosteric GABAA-receptor modulator. The inventions relate to the medical use of GT-002 in psychiatric disorders. The claims based on inventions from the results […]

Close-up of a hand holding a psilocybin capsule, symbolizing mental health treatment innovation.
Mental Wellness

Apex Labs Files for US Patent Protecting Psychedelic Drug Delivery System

Apex Labs Ltd. (APEX or the Company), a pharmaceutical company transforming the standard of mental health care with psilocybin is pleased to announce the filing of a provisional patent application with the United States Patent and Trademark Office (USPTO). The patent application applies to APEX’s uniquely formulated capsule which will be used for PATHFINDER-52 and SUMMIT-90 phase 2b clinical trials and in […]

Gateways Sensory Room
Mental Wellness

Gateways Hospital and Mental Health Center Opens New Sensory Room, Providing Vulnerable Clients with Innovative, Client-Centered Care

Gateways Hospital and Mental Health Center unveiled its groundbreaking Sensory Room, a pioneering addition to acute patient care in Los Angeles, generously funded by a $45,000 grant from the Robert Ellis Simon Foundation. This innovative space signifies Gateways’ commitment to implementing client-centered approaches, blending the latest inpatient psychiatric care practices with immersive sensory interventions, meaningful activities, and fostering […]

Alpha-synuclein Pathology Detection in Alzheimer's Disease
Mental Wellness

New Paper Published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, Demonstrates Correlation Between the Presence of Misfolded α-Synuclein and Clinical Presentations of Alzheimer’s Disease

Amprion is pleased to be affiliated with a new scientific paper published in Alzheimer’s & Dementia, entitled “Investigating alpha-synuclein co-pathology in Alzheimer’s disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay,” led by University of Perugia Professor, Dr. Lucilla Parnetti and Amprion Director of Research and Development, Dr. Luis Concha-Marambio. In this study, the α-Synuclein Seed Amplification Assay […]